Company Reports

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Sartorius Group reported second-quarter results with 7.9% organic sales growth, excluding US tariff surcharge compensation and currency effects, and underlying EBITDA margin expanding to 30.8% from 29.9% year over year. Management confirmed their full-year guidance.

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Sartorius Group reported its preliminary full-year 2025 results with 7.6% growth in constant currencies and an adjusted EBITDA margin of 29.7%, both in line with the company-compiled consensus.

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge through market leadership in bioreactors, which are core components of the biomanufacturing process.

Sartorius Group reported positive third-quarter results as revenue and adjusted EBITDA were above company-compiled consensus. Sales increased 10.6% in constant currency, and adjusted EBITDA increased by 14.8%. Shares are trading 10% higher intraday.

Sartorius Group reported its second-quarter 2025 results, where the slight revenue miss was offset by an underlying EBITDA beat against company-reported consensus. Sales increased 5.7% in constant currency, while underlying EBITDA increased by 11.5%. Shares are trading 10% lower intraday on July 22.

We are transferring coverage of Sartorius AG and its subsidiary Sartorius Stedim Biotech—both active in biopharmaceutical equipment and laboratory consumables—to a new analyst. Sartorius Stedim Biotech accounts for approximately 80% of group revenue and 89% of EBIT.

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge through market leadership in bioreactors, which are core components of the biomanufacturing process.

Sartorius AG reported its first-quarter 2025 results, exceeding company-compiled consensus estimates. Sales and adjusted EBITDA increased in constant currency by 6.5% and 12.2%, respectively. Shares are trading 4% higher intraday.

Wide-moat Sartorius AG and its bioprocessing subsidiary wide-moat Sartorius Stedim Biotech reported third-quarter earnings broadly in line with our expectations, but more pertinently management signalled an imminent end to the customer destocking that has weighed on sentiment and fuelled uncertainty. This comes after they revised full-year guidance downward at the midyear results, citing an uncertain recovery time line. Both companies’ shares are trading up over 15% intraday as a result. With no changes to our forecasts, we maintain our fair value estimates of EUR 265 and EUR 215 for Sartorius AG preference shares and Sartorius Stedim, respectively.

Wide-moat Sartorius AG and its bioprocessing subsidiary wide-moat Sartorius Stedim Biotech, or SSB, reported second-quarter earnings that were in line with our expectations. However, the companies revised their full-year guidance downward, based on slow and uncertain recovery momentum. We pushed out our post-covid recovery trajectories by one year and lowered our midterm growth forecasts to reflect a slowdown in China. For Sartorius AG preference shares, we lowered our fair value estimate to EUR 265 from EUR 295. For Sartorius Stedim, we lowered our fair value estimate to EUR 215 from EUR 240. We think the long-term story remains intact and currently view the shares as undervalued, but acknowledge that the near-term outlook is uncertain.

Sartorius AG is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. It offers products and services for life science labs and bioprocessing. For bioprocessing, Sartorius performs consultations and custom installations of biomanufacturing systems for its drugmaker clients, which include bioreactors, filtration and purification systems, and cell analysis systems. This equipment has high disposable consumable requirements, including single-use bioreactor bags, filters, tubes, and containers. The company’s proven expertise in single-use technology, or SUT, and the regulation-validated nature of biomanufacturing gives Sartorius an attractive razor-and-blades model and supports a wide economic moat.

Wide-moat Sartorius and its bioprocessing subsidiary Sartorius Stedim Biotech, or SSB, reported first-quarter earnings that were a modest disappointment to us, with revenue mildly lower than our forecast. However, we continue to see early signs of recovery in the order books, and think that the company is still on track to meet its full-year guidance. We are maintaining our fair value estimates of EUR 295 per Sartorius AG preference share and EUR 240 per SSB share, and we view the current prices as slightly cheap with a slight preference for SSB.

Wide-moat companies Sartorius AG and its bioprocessing subsidiary Sartorius Stedim Biotech, or SSB, reported preliminary full-year results that were slightly below expectations. More significantly, the companies provided midterm guidance out until 2028 that were in line with expectations. We maintain our fair value estimates of EUR 295 per Sartorius AG preference share and EUR 240 per SSB share, and view the current prices as fairly valued.

We are transferring coverage of Sartorius AG and its bioprocessing subsidiary Sartorius Stedim Biotech, or SSB. We maintain our wide moat ratings for both companies due to the high regulatory hurdles of validated biomanufacturing and Sartorius’ excellent reputation for single-use technologies. However, we are reducing our fair value estimates on both companies due to our higher long-term cost of sales assumptions. For Sartorius AG, we revise our fair value downward to EUR 295 per preference share from EUR 315 previously. For SSB, we revise our fair value to EUR 240 per share from EUR 287.

Sartorius AG is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. It offers products and services for life science labs and bioprocessing. For bioprocessing, Sartorius performs consultations and custom installations of biomanufacturing systems for its drugmaker clients, which include bioreactors, filtration and purification systems, and cell analysis systems. This equipment has high disposable consumable requirements, including single-use bioreactor bags, filters, tubes, and containers. The company’s proven expertise in single-use technology, or SUT, and the regulation-validated nature of biomanufacturing gives Sartorius an attractive razor-and-blades model and supports a wide economic moat.

Sartorius AG and Sartorius Stedim Biotech’s third-quarter 2023 results were largely in line with expectations, and we are making no changes to our fair value estimates. Shares for both wide-moat companies currently look slightly undervalued, after falling due to last week’s update on preliminary third-quarter results and lowered full-year guidance. We believe it may be a good opportunity for investors to obtain shares at a discounted price, given that Sartorius reported seeing signs of recovery late in the third quarter. Order intake started improving toward the end of the third quarter, suggesting declines hit a floor in the second quarter and showed signs of recovery in the bioprocessing business, albeit at a slow pace. Shares are up slightly on these trends. However, uncertainty from macroeconomic and geopolitical factors remains elevated, and a full recovery in demand may be gradual heading into 2024.

Management for wide-moat companies Sartorius AG and its bioprocessing subsidiary, Sartorius Stedim Biotech, reduced full-year fiscal 2023 guidance and announced preliminary third-quarter results that showed softness. After adjusting our forecasts to incorporate the weaker full-year expectations, we are maintaining our fair value estimates for both firms. Macroeconomic headwinds, uncertainty around investments by biopharmaceutical customers, and tough comparable periods may plague the firm for longer than previously expected, and this is the second time this year management has lowered full-year guidance due to these factors. Nevertheless, longer-term growth drivers for the Sartorius companies remain sound, in our opinion, and if shares decline substantially on this news, we think investors may want to view that as an opportunity to invest in strong life science with stellar long-term prospects.